Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025. The Retina World Congress 2025, led ...

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based ...

Ophthalmologist Dilraj Grewal explores cutting-edge clinical trials for uveitis treatment, highlighting new targeted therapies that aim to control inflammation and macular edema with fewer ...

Lexitas Pharma Services' CMO discusses groundbreaking ophthalmology conference, emphasizing innovative clinical trials, emerging treatments for eye diseases, and the potential for transformative ...

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration.

Sophie X. Deng, MD, PhD, FARVO, has stepped into the role as the new 2025-2026 Association for Research and Ophthalmology (ARVO) president. Deng has been part of ARVO for more than 20 years, is a ...

Study reveals faricimab effectively treats diabetic macular edema in underrepresented minorities, showing significant visual acuity improvements and safety across diverse patient populations. Johns ...

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based ...

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.